These trials completed more than 12 months ago and should have reported results. Some have, some have not.

These trials are not yet due to report results: some are ongoing, some completed within the past 12 months.

These trials have problematic data on the registry. Details why »

Status Trial ID Title Completion date Category
Listed as ongoing, but also has a completion date and reported results 2004-000327-15 A Phase 3 Multicenter, Open-label, Randomized Study of XL119 Versus 5-Fluorouracil (5-FU) plus Leucovorin (LV) in Subjects with Advanced Biliary Tumors Not Amenable to Conventional Surgery 2006-12-06 bad-data
Listed as ongoing, but also has a completion date 2008-002320-29 An International, Randomized, Double-Blinded, Phase 3 Efficacy Study of XL184 versus Placebo in Subjects with Unresectable, Locally Advanced, or Metastatic Medullary Thyroid Cancer 2020-03-06 bad-data
Not reported 2009-012964-14 A randomized discontinuation study of XL184 in subjects with advanced solid tumors 2014-06-23 due-trials
Ongoing, reported early 2009-016707-30 A Phase 2 Study of XL147 in Subjects with Advanced or Recurrent Endometrial Carcinoma not-yet-due
Exempt, with results 2009-016862-10 A Phase 1/2 Study of XL147 Administered in Combination with Trastuzumab or Paclitaxel and Trastuzumab in Subjects with Metastatic Breast Cancer who have Progressed on a Previous Trastuzumab- Based Reg... not-yet-due
Not reported 2012-001426-99 A Phase 3, randomized, double-blind, controlled trial of cabozantinib (XL184) vs. mitoxantrone plus prednisone in men with previously treated symptomatic castration-resistant prostate cancer 2015-01-13 due-trials
Not reported 2012-001834-33 A Phase 3, Randomized, Double-blind, Controlled Study of Cabozantinib (XL184) vs. Prednisone in Metastatic Castration-resistant Prostate Cancer Patients who have Received Prior Docetaxel and Prior Abi... 2015-05-25 due-trials
Ongoing 2013-001001-91 A Phase 3, Randomized, Double-blind, Controlled Study of Cabozantinib (XL184) vs Placebo in Subjects with Hepatocellular Carcinoma Who Have Received Prior Sorafenib. not-yet-due
Ongoing 2013-001010-14 A Phase 3, Randomized, Controlled Study of Cabozantinib (XL184) vs Everolimus in Subjects with Metastatic Renal Cell Carcinoma that has Progressed after Prior VEGFR Tyrosine Kinase Inhibitor Therapy not-yet-due
Ongoing 2013-003402-40 A Randomized, Double-blind Study To Evaluate the Efficacy not-yet-due
Other 2018-001771-21 A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of Cabozantinib (XL184) in Subjects with Radioiodine-Refractory Differentiated Thyroid Cancer Who Have Progressed after Prior VEGFR-Target... not-yet-due
Ongoing 2018-003354-24 A Randomized, Controlled Phase 3 Study of Cabozantinib (XL184) in Combination with Atezolizumab versus Sorafenib in Subjects with Advanced Hepatocellular Carcinoma Who Have Not Received Previous Syste... not-yet-due
Ongoing 2018-004567-31 A Randomized, Double-Blind, Controlled Phase 3 Study of Cabozantinib in Combination with Nivolumab and Ipilimumab versus Nivolumab and Ipilimumab in Subjects with Previously Untreated Advanced or Meta... not-yet-due
Ongoing 2020-000348-77 A Phase 3, Randomized, Open-Label, Controlled Study of Cabozantinib (XL184) in Combination with Atezolizumab vs Second Novel Hormonal Therapy (NHT) in Subjects with Metastatic Castration-Resistant Pro... not-yet-due